News & Updates
Filter by Specialty:
Effective PrEP averts further cost for HIV treatment
Effective treatment with pre-exposure prophylaxis (PrEP) for HIV puts a cap on the additional cost patients should be willing to pay for long-acting injectable cabotegravir (CAB-LA), reports a US study.
Effective PrEP averts further cost for HIV treatment
02 Mar 2022
Ligelizumab improves symptoms, QoL in patients with urticaria
In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.
Ligelizumab improves symptoms, QoL in patients with urticaria
02 Mar 2022
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
01 Mar 2022
NOACs better than warfarin in diabetic patients with atrial fibrillation
Treatment with nonvitamin K antagonist oral anticoagulants (NOACs) results in lower risks of diabetes complications and mortality compared with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus (DM), suggest a study.
NOACs better than warfarin in diabetic patients with atrial fibrillation
01 Mar 2022
High-dose ipilimumab augments nivolumab benefit for TCC
In the phase II TITAN-TCC* trial presented at ASCO GU 2022, the addition of ipilimumab to nivolumab led to improved responses in patients with pretreated (second/third line) advanced/metastatic or surgically unresectable transitional cell carcinoma (TCC).